Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products

Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products ORIGINAL INVESTIGATION Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products Buyer Beware! Ram Y. Gordon, MD; Tod Cooperman, MD; William Obermeyer, PhD; David J. Becker, MD Background: Red yeast rice (RYR) is a widely avail- Results: There was marked variability in the 12 RYR prod- able dietary supplement used by millions of patients as ucts in total monacolins (0.31-11.15 mg/capsule), mo- an alternative therapy for hyperlipidemia. It contains 14 nacolin K (lovastatin) (0.10-10.09 mg/capsule), and mo- active compounds called monacolins that inhibit he- nacolin KA (0.00-2.30 mg/capsule). Four products had patic cholesterol synthesis. Although studies have sug- elevated levels of citrinin. gested that some formulations of RYR may be effective and safe for lipid lowering, monacolin levels are not stan- Conclusions: We found striking variability in monaco- dardized among marketed products and are generally not lin content in 12 proprietary RYR products and the pres- published on labels. We evaluated monacolin levels in ence of citrinin in one-third of the formulations tested. 12 commercial RYR formulations and tested for citri- Although RYR may have potential as an alternative lipid- nin, a mycotoxin that is nephrotoxic in animals. lowering agent, our findings suggest the need for im- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products

Loading next page...
 
/lp/american-medical-association/marked-variability-of-monacolin-levels-in-commercial-red-yeast-rice-dRInULhCOD
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2010.382
pmid
20975018
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products Buyer Beware! Ram Y. Gordon, MD; Tod Cooperman, MD; William Obermeyer, PhD; David J. Becker, MD Background: Red yeast rice (RYR) is a widely avail- Results: There was marked variability in the 12 RYR prod- able dietary supplement used by millions of patients as ucts in total monacolins (0.31-11.15 mg/capsule), mo- an alternative therapy for hyperlipidemia. It contains 14 nacolin K (lovastatin) (0.10-10.09 mg/capsule), and mo- active compounds called monacolins that inhibit he- nacolin KA (0.00-2.30 mg/capsule). Four products had patic cholesterol synthesis. Although studies have sug- elevated levels of citrinin. gested that some formulations of RYR may be effective and safe for lipid lowering, monacolin levels are not stan- Conclusions: We found striking variability in monaco- dardized among marketed products and are generally not lin content in 12 proprietary RYR products and the pres- published on labels. We evaluated monacolin levels in ence of citrinin in one-third of the formulations tested. 12 commercial RYR formulations and tested for citri- Although RYR may have potential as an alternative lipid- nin, a mycotoxin that is nephrotoxic in animals. lowering agent, our findings suggest the need for im-

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Oct 25, 2010

References